Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

CytRx reports $4.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

New caproKits enable investigation of small molecule–protein interactions

New caproKits enable investigation of small molecule–protein interactions

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta second-quarter net loss increases to $9.1 million

Synta second-quarter net loss increases to $9.1 million

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML